23 Feb DiscGenics
Flagg Flanagan, CEO and Chairman
Oct. 6 | 11:45am | FLW Ballroom F
Salt Lake City, UT
(Private)
DiscGenics is a privately held, late-stage clinical biopharmaceutical company focused on developing regenerative therapies for musculoskeletal degeneration. Its lead product candidate, IDCT (injectable disc cell therapy, or rebonuputemcel), is a single-injection biologic treatment designed to halt the progression of lumbar disc degeneration and regenerate the disc from within. The active component of IDCT is a live, manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, delivered via a viscous carrier. A successful combined Phase I/II clinical study of IDCT has been completed, and the company is preparing for a U.S.-based Phase III trial targeting pain and disability associated with lumbar disc disease. IDCT has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration. To maintain control over quality, compliance, cost, and timelines, DiscGenics has built and validated in-house manufacturing capabilities and is advancing a next-generation allogeneic cell platform for future indications.
